Tumor necrosis factor-α-converting enzyme: Its role in community-acquired pneumonia

Journal of Infectious Diseases

Volumn 186, Issue 12, 2002, Pages 1790-1796

  Greene, Catherine ^a   Lowe, Gregory ^a   Taggart, Clifford ^a   Gallagher, Paula ^a   McElvaney, Noel ^a   O'Neill, Shane ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ENZYME ANTIBODY; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCLONAL ANTIBODY M220; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL COMPARTMENTALIZATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; COMMUNITY CARE; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENZYME ANALYSIS; FEMALE; HUMAN; INTERNALIZATION; LUNG FLUID; LUNG INFECTION; LUNG LAVAGE; LUNG LOBE; MALE; MEDIATOR RELEASE; MEMBRANE BINDING; PNEUMONIA; PRIORITY JOURNAL;

ADAM PROTEINS; BRONCHOALVEOLAR LAVAGE FLUID; CELL COUNT; COMMUNITY-ACQUIRED INFECTIONS; DOWN-REGULATION; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-10; INTERLEUKIN-6; MALE; METALLOENDOPEPTIDASES; MIDDLE AGED; PNEUMONIA; RECEPTORS, INTERLEUKIN-1; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037115091     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345799     Document Type: Article

References (50)

1. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Clarke MJ, Berkelman RL. Infectious disease in the United States. JAMA 1996;275:189-93.
2. Center for Disease Control and Prevention. Premature deaths, monthly mortality and monthly physician contacts: United States. MMWR Morb Mortal Wkly Rep 1997;46:556-61.
3. Arston BJ, Plouffe JF, File TM Jr, et al. Incidence of community-acquired pneumonia requiring hospitalisation: Results of a population-based active surveillance study in Ohio. The Community-Based Incidence Study Group. Arch Intern Med 1997;157:1709-22.
4. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998;20:820-37.
5. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis. JAMA 1996;275:134-41.
6. Monton C, Torres A, El-Ebiary M, Filella X, Xaubet A, de la Bellacasa JP. Cytokine expression in severe pneumonia: A bronchoalveolar lavage study. Crit Care Med 1999;27:1745-53.
7. Kosmas EN, Baxevanis CN, Papamichail M, Kordossis T. Daily variation in circulating cytokines and acute-phase proteins correlates with clinical and laboratory indices in community-acquired pneumonia. Eur J Clin Invest 1997;27:308-15.
8. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest 1995;107:1342-9.
9. Dehoux MS, Boutten A, Ostinelli J, et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994;150:710-6.
10. Glynn P, Coakley R, Kilgallen I, Murphy N, O'Neill SJ. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 1999;54:51-5.
11. Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases TNF-α from cells. Nature 1997;385:729-33.
12. Nelson S, Bagby GJ, Bainton BG, Wilson LA, Thompson JJ, Summer WR. Compartmentalization of intraalveolar and systemic lipopolysaccharide-induced tumor necrosis factor and the pulmonary inflammatory response. J Infect Dis 1989;159:189-94.
13. Boutten A, Dehoux MS, Seta N, et al. Compartmentalised IL-8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1996;153:336-42.
14. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001;163:316-21.
15. Peschon JJ, Slack JL, Reddy P, et al. An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281-4.
16. Hansen HP, Dietrich S, Kisseleva T, et al. CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme. J Immunol 2000;165:6703-9.
17. Lum L, Wong BR, Josien R, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999;274:13613-8.
18. Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ. Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: The metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology 2000;141:4342-8.
19. Rovida E, Paccagnini A, Del Rosso M, Peschon J, Dello Sbarba P. TNF-alpha-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. J Immunol 2001;166:1583-9.
20. Garton KJ, Gough PJ, Blobel CP, et al. TACE (ADAM17) mediates the cleavage and shedding of Fractalkine (CX3CLI). J Biol Chem 2001;276:37993-8001.
21. Montero JC, Yuste L, Diaz-Rodriguez E, Esparis-Ogando A, Pandiella A. Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. Mol Cell Neurosci 2000;16:631-48.
22. Rio C, Buxbaum JD, Peschon JJ, Corfas G. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. J Biol Chem 2000;275:10379-87.
23. Buxbaum JD, Liu KN, Luo Y, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998;273:27765-7.
24. Reddy P, Slack JL, Davis R, et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem 2000;275:14608-14.
25. Althoff K, Reddy P, Voltz N, Rose-John S, Mullberg J. Shedding of interleukin-6 receptor and tumor necrosis factor alpha: Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur J Biochem 2000;267:2624-31.
26. Montero-Julian FA. The soluble IL-6 receptors: Serum levels and biological function. Cell Mol Biol (Noisy-le-grand) 2001;4:583-97.
27. Hurst SM, Wilkinson TS, McLoughlin RM, et al. IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 2001;14:705-14.
28. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50.
29. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-74.
30. Klech H, Pohl W. Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Report of the European Society of Pneumology Task Group. Eur Respir J 1989;2:561-84.
31. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Guidelines from the Infectious Diseases Society of America: Practical guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000;31:347-82.
32. Niederman MS, Bass JB Jr, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993;148:1418-26.
33. Rennard SI, Basset G, Lecossier D, et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as a marker of dilution. J Appl Physiol 1986;60:532-8.
34. Flick DA, Gifford GE. Comparison of in vitro cell cytotoxic assays for tumour necrosis factor. J Immunol Methods 1984;68:167-75.
35. Kamentsky LA, Burger DE, Gershman RJ, Kamentsky LD, Luther E. Slide-based laser scanning cytometry. Acta Cytol 1997;41:123-43.
36. Woltmann G, Ward R, Symon F, Rew D, Pavord I, Wardlaw A. Objective quantitative analysis of eosinophils and bronchial epithelial cells in induced sputum by laser scanning cytometry. Thorax 1999;54:124-30.
37. Luettig B, Decker T, Lohmann-Matthes ML. Evidence for the existence of two forms of membrane tumour necrosis factor: An integral protein and a molecule attached to its receptor. J Immunol 1989;143:4034-8.
38. Dinerallo C. A. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-47.
39. Doedens JR, Black RA. Stimulation-induced down-regulation of tumour necrosis factor-α-converting enzyme. J Biol Chem 2000;275:14598-607.
40. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist. J Clin Invest 1990;85:1694-97.
41. Arend WP, Malyak M, Smith MF, et al. Binding of IL-1α, IL-1β and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluid. J Immunol 1994;153:4766-74.
42. Rooney M, Varsani H, Martin K, Lombard PR, Dayer JM, Woo P. Tumour necrosis factor-α and its receptors in juvenile chronic arthritis. Rheumatology 2000;39:432-8.
43. O'Grady NP, Preas HL, Pugin J, et al. Local inflammatory responses following bronchial endotoxin instillation in humans. Am J Respir Crit Care Med 2001;163:1591-8.
44. Re F, Muzio M, De Rossi M et al. The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: Characterisation of induction by dexamethasone and ligand binding properties of the released decoy receptor. J Exp Med 1994;179:739-43.
45. Thabard W, Collette M, Mellerin MP, et al. IL-6 upregulates its own receptor on some human myeloma cell lines. Cytokine 2001;14:352-6.
46. Remick DG, Call DR, Ebong SJ, et al. Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality. Crit Care Med 2001;29:473-81.
47. Cox G. IL-10 enhances resolution of pulmonary inflammation in vivo by promoting apoptosis of neutrophils. Am J Physiol 1996;271:L566-71.
48. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147:3815-22.
49. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SFI. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996;174:994-1000.
50. Coeshott C, Ohnemus C, Pilyavskaya A, et al. Converting enzyme-independent release of tumor necrosis factor alpha and IL-1beta from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3. Proc Natl Acad Sci USA 1999;96:6261-6.